CareDx director sells shares, exercises options

CareDx, Inc. director Hannah Valantine reported multiple equity transactions in Common Stock on July 16, 2026.

Rhea-AI Filing Summary

CareDx, Inc. director Hannah Valantine reported multiple equity transactions in Common Stock on July 16, 2026. She sold a total of 28,779 shares, including 28,679 shares at a weighted average price of $36.1445 (individual trades from $35.55 to $36.50) and 100 shares at $36.55, under a Rule 10b5-1 trading plan adopted on December 11, 2025. She also exercised fully vested stock options for 28,779 shares at exercise prices of $7.96, $14.19 and $20.56 per share. Following the reported transactions, she held 36,786 shares of CareDx Common Stock directly.

Insider Trade Summary 10b5-1

Exercise and Sale: 28,779 shares ($615K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Valantine Hannah

Role Director

Sold 28,779 shs ($1.04M)

Approx. gross sale proceeds $1.04M

Approx. exercise cost $425K

Approx. pre-tax spread $615K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	7,606	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	16,048	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	5,125	$0.00	$0.00
Exercise	Common Stock	7,606	$20.56	$156K
Exercise	Common Stock	16,048	$14.19	$228K
Exercise	Common Stock	5,125	$7.96	$41K
Sale	Common Stock F1, F2	28,679	$36.1445	$1.04M
Sale	Common Stock F1	100	$36.55	$4K

Holdings After Transaction: Stock Option (Right to Buy) — 24,011 contracts (Direct); Common Stock — 36,686 shares (Direct)

Footnotes (3)

1. F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The option is fully vested.

Key Figures

Shares sold: 28,779 shares Weighted avg sale price: $36.1445 per share Additional sale price: $36.55 per share +3 more

6 metrics

Shares sold 28,779 shares Aggregate CareDx Common Stock sold on 2026-07-16

Weighted avg sale price $36.1445 per share For 28,679 shares sold in multiple trades between $35.55 and $36.50

Additional sale price $36.55 per share Price for 100 CareDx Common shares sold on 2026-07-16

Options exercised 28,779 shares Common shares acquired via option exercises at $7.96, $14.19 and $20.56

Post-transaction holdings 36,786 shares Direct CareDx Common Stock ownership after reported transactions on 2026-07-16

Rule 10b5-1 plan adoption December 11, 2025 Adoption date of trading plan governing the reported stock sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CareDx (CDNA) director Hannah Valantine report?

Hannah Valantine reported selling 28,779 CareDx shares and exercising stock options for 28,779 shares of Common Stock on July 16, 2026. The sales were open-market transactions and the option exercises converted derivative awards into common shares.

How many CareDx (CDNA) shares did Hannah Valantine sell and at what prices?

She sold 28,779 shares of CareDx Common Stock. This included 28,679 shares at a weighted average price of $36.1445 per share, with individual trades from $35.55 to $36.50, and an additional 100 shares at $36.55 per share.

Were Hannah Valantine’s CareDx (CDNA) share sales under a Rule 10b5-1 plan?

Yes. The reported sale was effected under a Rule 10b5-1 trading plan adopted by Hannah Valantine on December 11, 2025. Such plans pre-establish trading parameters, providing a structured framework for future insider transactions.

How many CareDx (CDNA) shares does Hannah Valantine own after these transactions?

After the reported July 16, 2026 transactions, Hannah Valantine reported direct ownership of 36,786 shares of CareDx Common Stock. This figure reflects the combined effect of her option exercises and subsequent open-market sales reported in this Form 4.

What stock options did Hannah Valantine exercise in CareDx (CDNA)?

She exercised fully vested stock options covering 28,779 shares of CareDx Common Stock. The options had exercise prices of $7.96, $14.19 and $20.56 per share, and the corresponding option positions were reduced as they were converted into common shares.

What is the relationship between the shares sold and options exercised by Hannah Valantine in CareDx (CDNA)?

On July 16, 2026, she both exercised options for 28,779 shares and sold 28,779 shares of Common Stock. While the filing does not tie specific sales to specific exercises, the share counts for exercised options and shares sold match in aggregate.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		M		7,606	A	$20.56	44,292	D
Common Stock	07/16/2026		M		16,048	A	$14.19	60,340	D
Common Stock	07/16/2026		M		5,125	A	$7.96	65,465	D
Common Stock	07/16/2026		S(1)		28,679	D	$36.1445(2)	36,786	D
Common Stock	07/16/2026		S(1)		100	D	$36.55	36,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.56	07/16/2026		M			7,606	(3)	06/15/2032	Common Stock	7,606	$0	0	D
Stock Option (Right to Buy)	$14.19	07/16/2026		M			16,048	(3)	06/13/2034	Common Stock	16,048	$0	0	D
Stock Option (Right to Buy)	$7.96	07/16/2026		M			5,125	(3)	06/15/2033	Common Stock	5,125	$0	24,011	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option is fully vested.

	/s/ Jeffrey Adam Novack, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)